{"id":830,"date":"2014-04-17T14:51:18","date_gmt":"2014-04-17T12:51:18","guid":{"rendered":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg"},"modified":"2014-04-17T14:51:18","modified_gmt":"2014-04-17T12:51:18","slug":"figur7-2","status":"inherit","type":"attachment","link":"https:\/\/dextechmedical.com\/en\/prostate-cancer\/figur7-2\/","title":{"rendered":"figur7"},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-830","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>figur7 | DexTech<\/title>\n<meta name=\"description\" content=\"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"figur7 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"470\" \/>\n\t<meta property=\"og:image:height\" content=\"333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\",\"url\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\",\"name\":\"figur7 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2014-04-17T12:51:18+00:00\",\"description\":\"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prostate cancer\",\"item\":\"https:\/\/dextechmedical.com\/en\/prostate-cancer\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"figur7\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"figur7 | DexTech","description":"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","og_locale":"en_US","og_type":"article","og_title":"figur7 | DexTech","og_description":"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.","og_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","og_site_name":"DexTech","og_image":[{"width":470,"height":333,"url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","type":"image\/jpeg"}],"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","name":"figur7 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2014-04-17T12:51:18+00:00","description":"Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5.","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Prostate cancer","item":"https:\/\/dextechmedical.com\/en\/prostate-cancer\/"},{"@type":"ListItem","position":3,"name":"figur7"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg'><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"212\" src=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7-300x212.jpg\" class=\"attachment-medium size-medium\" alt=\"\" srcset=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7-300x212.jpg 300w, https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg 470w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5. <\/p>\n"},"caption":{"rendered":"<p>Figur 7: y-axeln = PSA mikrog\/L, x-axeln = tid. Bilden visar en typisk CRPC-patient och sjukdomsf\u00f6rloppet. Y-axeln beskriver canceraktiviteten, PSA, hos en patient d\u00e4r medicinering (bl\u00e5 pilar) minskar canceraktiviteten men d\u00e4r patienten efter en tid utvecklar resistens mot medicineringen varvid PSA \u00e5terigen \u00f6kar. Patienten f\u00e5r d\u00e4rf\u00f6r ett nytt l\u00e4kemedel och cykeln upprepas till dess att det inte finns n\u00e5gra alternativa l\u00e4kemedel att tillg\u00e5. <\/p>\n"},"alt_text":"","media_type":"image","mime_type":"image\/jpeg","media_details":{"width":470,"height":333,"file":"figur7.jpg","sizes":{"thumbnail":{"file":"figur7-150x150.jpg","width":150,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7-150x150.jpg"},"medium":{"file":"figur7-300x212.jpg","width":300,"height":212,"mime_type":"image\/jpeg","source_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7-300x212.jpg"},"full":{"file":"figur7.jpg","width":470,"height":333,"mime_type":"image\/jpeg","source_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg"}},"image_meta":{"aperture":0,"credit":"","camera":"","caption":"","created_timestamp":0,"copyright":"","focal_length":0,"iso":0,"shutter_speed":0,"title":""}},"post":267,"source_url":"https:\/\/dextechmedical.com\/wp-content\/uploads\/figur7.jpg","_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media\/830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=830"}]}}